Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02254486 · ClinicalTrials.gov registry record · Phase 3

Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults

A Phase 3 study of Colon Cancer and Colorectal Carcinoma, sponsored by Norgine.

Completed
Registry status
Phase 3
Development phase
621
Enrollment target
12
Study locations

NCT02254486: Completed Phase 3 study of Colon Cancer and Colorectal Carcinoma, sponsored by Norgine.

NCT02254486 is a Phase 3 study of Colon Cancer and Colorectal Carcinoma that has completed, run by Norgine. The registered enrollment target is 621 participants, below the 4,450-participant average among 97 other Colon Cancer trials with a reported enrollment target (86% lower). The trial reports 12 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02254486, a Phase 3 study of Colon Cancer and Colorectal Carcinoma, has completed, sponsored by Norgine.

COMPLETED
Registry status
Phase 3
Development phase
621 participants
Enrollment target
12
Study locations

Study Summary

This study evaluates the efficacy, safety and tolerability of NER1006 versus Trisulfate Solution (TS) in adult patients requiring bowel cleansing prior to any procedure that requires a clean bowel, using a 2-Day evening/morning Split-Dosing regimen. Approximately 540 patients will be randomised with the aim of achieving a minimum of 245 patients in each of the 2 groups.

Primary Outcome

The overall quality of bowel cleansing was assessed by a blinded central reader (an experienced and trained colonoscopist) using the segmental scores of the Harefield Cleansing Scale (HCS). A final HCS grading of A, B, C or D was derived. Grades A and B are classified as successful (i.e., all mucosa could be visualised) and C and D are classified as unsuccessful. Comparison of overall success of cleansing with NER1006 versus Trisulfate solution was evaluated using a non-inferiority study design.

Interventions

  • DRUG NER1006
  • DRUG Trisulfate solution

Study Locations (12)

North Carolina

  • Cumberland Research Associates, LLC - Fayetteville
  • Peters Medical Research - High Point
  • Wake Research Associates, LLC - Raleigh
  • Trial Management Associates, LLC - Wilmington

Maryland

  • Investigative Clinical Research - Annapolis
  • MGG Group Co., Inc., Chevy Chase Clinical - Chevy Chase

Ohio

  • Consultants for Clinical Research - Cincinnati
  • Investigative Clinical Research, LLC - Mentor

California

  • Anaheim Clinical Trials - Anaheim

Michigan

  • Clinical Research Institute of Michigan, LLC - Chesterfield

New York

  • Long Island Gastrointestinal Research Group, LLP - Great Neck

Utah

  • Advanced Research Institute - Ogden

Trial Details

FieldValue
Enrollment Target 621 participants
Start Date 2014-09
Est. Completion 2015-06
Phase Phase 3
Norgine

2 total trials

What the finished NCT02254486 record still lists

NCT02254486 is an interventional study that assigns participants to a tested intervention. The registered 621 participants enrollment target is mid-sized for trials with a published cap, below the 4,450-participant average among 97 other Colon Cancer trials with a reported enrollment target (86% lower).

The record links to 3 conditions, with Colon Cancer appearing as the primary indexed condition, and to 2 interventions - of which NER1006 is the first listed.

NCT02254486 lists 12 locations in 7 states (North Carolina, Maryland, Ohio).

Frequently Asked Questions

What is clinical trial NCT02254486 about?

NCT02254486 is a clinical study titled "Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults". This study evaluates the efficacy, safety and tolerability of NER1006 versus Trisulfate Solution (TS) in adult patients requiring bowel cleansing prior to any procedure that requires a clean bowel, using a 2-Day evening/morning Split-Dosing regimen. Approximately 540 patients will be randomised with...

What is the current status of trial NCT02254486?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 621 participants. The study started on 2014-09. Estimated completion is 2015-06.

What conditions does trial NCT02254486 study?

This clinical trial studies the following conditions: Colon Cancer, Colorectal Carcinoma, Colon Cleansing.

What interventions are being tested in trial NCT02254486?

The interventions under investigation include: NER1006 (DRUG), Trisulfate solution (DRUG).

Who is sponsoring clinical trial NCT02254486?

This trial is sponsored by Norgine, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02254486 being conducted?

This trial has 12 study locations across California, Maryland, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colon Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02254486's enrollment target sits among peer trials

621 18th of 97 higher than 80 of 97 other Colon Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Colon Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06712355 · 621 participants · Phase 3

    Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  • NCT02282969 · 620 participants

    PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing

  • NCT02838836 · 620 participants

    Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

  • NCT05538910 · 620 participants · NA

    Defining Neurobiological Links Between Substance Use and Mental Illness

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02254486, the US trial registry maintained by the National Library of Medicine. NCT02254486 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.